Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
LXEO · NASDAQ · Biological Products, (No Diagnostic Substances)
Lexeo Therapeutics (LXEO) · oqro.io/stocks/LXEO · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$2.96+0.01 (+0.34%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
Insider trade · Traded Nov 17, 2026 · Filed Nov 18, 2026
CEO sold ~$11K of LXEO shares in the open marketSourceInsider trade · Traded Nov 17, 2026 · Filed Nov 18, 2026
CFO sold ~$3.3K of LXEO shares in the open marketSourceInsider trade · Traded Nov 17, 2026 · Filed Nov 18, 2026
Officer sold ~$4.2K of LXEO shares in the open marketSourcePlanned sale · Planned for Nov 17, 2026 · Notice filed Nov 17, 2026
Officer filed to sell about $11K of LXEO stockSourcePlanned sale · Planned for Nov 17, 2026 · Notice filed Nov 17, 2026
Officer filed to sell about $4.2K of LXEO stockSourcePlanned sale · Planned for Nov 17, 2026 · Notice filed Nov 17, 2026
Officer filed to sell about $3.3K of LXEO stockSource5%+ stake · Stake as of Sep 30, 2026 · Filed Nov 16, 2026
Paradigm BioCapital Advisors LP cut its LXEO stake below 5% (0%)Source5%+ stake · Stake as of Sep 30, 2026 · Filed Nov 16, 2026
OrbiMed Advisors LLC cut its LXEO stake below 5% (3.9%)Source5%+ stake · Stake as of Sep 30, 2026 · Filed Oct 13, 2026
JPMORGAN CHASE & CO. now owns 5.5% of LXEO as a passive investorSourceFund moves · Holdings as of Jun 30, 2026 (Q2 2026) · Filed Aug 14, 2026
Montanova Capital, LLC disclosed an increased position in LXEO for Q2 2026SourceFund moves · Holdings as of Jun 30, 2026 (Q2 2026) · Filed Aug 14, 2026
Frazier Life Sciences Management, L.P. disclosed an increased position in LXEO for Q2 2026SourceFund moves · Holdings as of Jun 30, 2026 (Q2 2026) · Filed Aug 14, 2026
Orbimed Advisors LLC disclosed an increased position in LXEO for Q2 2026SourceFund moves · Holdings as of Jun 30, 2026 (Q2 2026) · Filed Aug 14, 2026
Paradigm Biocapital Advisors LP disclosed a reduced position in LXEO for Q2 2026Fund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 15, 2026
Orbimed Advisors LLC disclosed an increased position in LXEO for Q1 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 15, 2026
Paradigm Biocapital Advisors LP disclosed an increased position in LXEO for Q1 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 15, 2026
Avoro Capital Advisors LLC disclosed a reduced position in LXEO for Q1 2026SourceFund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Mar 16, 2026
Avoro Capital Advisors LLC disclosed a new position in LXEO for Q4 2025SourceFund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Feb 17, 2026
Paradigm Biocapital Advisors LP disclosed a new position in LXEO for Q4 2025SourceFund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Feb 17, 2026
Ra Capital Management, L.P. disclosed a new position in LXEO for Q4 2025SourceFund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Feb 17, 2026
Orbimed Advisors LLC disclosed a new position in LXEO for Q4 2025SourceFund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Feb 17, 2026
Montanova Capital, LLC disclosed a new position in LXEO for Q4 2025Insider trade · Traded Aug 18, 2025 · Filed Sep 10, 2025
CEO sold ~$5.2K of LXEO shares in the open marketSourceInsider trade · Traded Aug 18, 2025 · Filed Aug 20, 2025
Officer sold ~$13K of LXEO shares in the open marketSourceInsider trade · Traded Aug 18, 2025 · Filed Aug 20, 2025
Officer sold ~$2.8K of LXEO shares in the open marketSourceInsider trade · Traded Aug 18, 2025 · Filed Aug 20, 2025
Officer sold ~$2.5K of LXEO shares in the open marketSourceInsider trade · Traded Aug 18, 2025 · Filed Aug 20, 2025
Officer sold ~$1.8K of LXEO shares in the open marketSourceInsider trade · Traded May 16, 2025 · Filed May 20, 2025
CEO sold ~$3K of LXEO shares in the open marketSourceInsider trade · Traded May 16, 2025 · Filed May 20, 2025
Officer sold ~$1K of LXEO shares in the open marketSourceInsider trade · Traded May 16, 2025 · Filed May 20, 2025
Officer sold ~$1.4K of LXEO shares in the open marketSourceInsider trade · Traded May 16, 2025 · Filed May 20, 2025
Officer sold ~$1.6K of LXEO shares in the open marketSourceInsider trade · Traded Feb 19, 2025 · Filed Feb 21, 2025
CEO sold ~$19K of LXEO shares in the open marketSourceInsider trade · Traded Feb 19, 2025 · Filed Feb 21, 2025
Officer sold ~$10K of LXEO shares in the open marketSourceInsider trade · Traded Feb 19, 2025 · Filed Feb 21, 2025
Officer sold ~$9.3K of LXEO shares in the open marketSourceInsider trade · Traded Feb 19, 2025 · Filed Feb 21, 2025
Officer sold ~$6.6K of LXEO shares in the open marketSourceInsider trade · Traded Dec 10, 2024 · Filed Dec 12, 2024
CEO sold ~$20K of LXEO shares in the open marketSourceInsider trade · Traded Nov 25, 2024 · Filed Nov 26, 2024
Director purchased ~$105K of LXEO shares in the open marketSourceFund moves · Holdings as of Sep 30, 2024 (Q3 2024) · Filed Nov 15, 2024
Frazier Life Sciences Management, L.P. disclosed a new position in LXEO for Q3 2024SourceFund moves · Holdings as of Sep 30, 2024 (Q3 2024) · Filed Nov 14, 2024
Eventide Asset Management, LLC disclosed a reduced position in LXEO for Q3 2024SourceInsider trade · Traded Nov 11, 2024 · Filed Nov 13, 2024
CEO sold ~$20K of LXEO shares in the open marketInsider trade · Traded Oct 10, 2024 · Filed Oct 15, 2024
CEO sold ~$40K of LXEO shares in the open marketSourceFund moves · Holdings as of Jun 30, 2025 (Q2 2025) · Filed Aug 14, 2025
Frazier Life Sciences Management, L.P. disclosed an increased position in LXEO for Q2 2025SourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 18, 2025
Frazier Life Sciences Management, L.P. disclosed a reduced position in LXEO for Q4 2024SourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 14, 2025
Eventide Asset Management, LLC disclosed a reduced position in LXEO for Q4 2024SourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 14, 2025
D1 Capital Partners L.P. disclosed a reduced position in LXEO for Q4 2024Source